OBJECTIVE: The subthalamic nucleus (STN) is a target in the surgical treatment of Parkinson's disease (PD). The mechanism by which electrical stimulation of the STN ameliorates symptoms of PD remains unknown. One consistent aspect of STN stimulation is the ability to reduce the dosage of dopaminergic medications; sometimes they can be eliminated altogether. Furthermore, nigrostriatal projection axons are apposed to the dorsal surface of the STN and are likely affected by the application of current in this region. We sought to determine whether STN stimulation could release endogenous striatal dopamine. METHODS: Five patients with PD, who had previously undergone surgical implantation of bilateral STN stimulators, underwent [(11)C]raclopride positron emission tomographic scanning. l-dopa was withheld for 12 hours, and both stimulators were turned off 9 hours before scanning. We assayed for striatal dopamine release by measuring radioligand displacement as a consequence of turning on the right STN stimulator after 45 minutes of a 90-minute [(11)C]raclopride infusion. Patients were evaluated with the motor section of the Unified Parkinson's Disease Rating Scale before and after the studies. RESULTS: Comparisons between the right and left striata, before and after right STN stimulation, demonstrated no significant differences in [(11)C]raclopride binding, despite significant improvements in Unified Parkinson's Disease Rating Scale motor scores with unilateral stimulation (mean improvement, 26.0 +/- 16.4%; P < 0.05). This finding was also noted when the striatum was partitioned into dorsal and ventral caudate and putamen and the four regions were analyzed separately. CONCLUSION: Our results suggest that STN stimulation does not mediate its anti-PD effects via the release of dopamine, as assessed with [(11)C]raclopride displacement.
OBJECTIVE: The subthalamic nucleus (STN) is a target in the surgical treatment of Parkinson's disease (PD). The mechanism by which electrical stimulation of the STN ameliorates symptoms of PD remains unknown. One consistent aspect of STN stimulation is the ability to reduce the dosage of dopaminergic medications; sometimes they can be eliminated altogether. Furthermore, nigrostriatal projection axons are apposed to the dorsal surface of the STN and are likely affected by the application of current in this region. We sought to determine whether STN stimulation could release endogenous striatal dopamine. METHODS: Five patients with PD, who had previously undergone surgical implantation of bilateral STN stimulators, underwent [(11)C]raclopride positron emission tomographic scanning. l-dopa was withheld for 12 hours, and both stimulators were turned off 9 hours before scanning. We assayed for striatal dopamine release by measuring radioligand displacement as a consequence of turning on the right STN stimulator after 45 minutes of a 90-minute [(11)C]raclopride infusion. Patients were evaluated with the motor section of the Unified Parkinson's Disease Rating Scale before and after the studies. RESULTS: Comparisons between the right and left striata, before and after right STN stimulation, demonstrated no significant differences in [(11)C]raclopride binding, despite significant improvements in Unified Parkinson's Disease Rating Scale motor scores with unilateral stimulation (mean improvement, 26.0 +/- 16.4%; P < 0.05). This finding was also noted when the striatum was partitioned into dorsal and ventral caudate and putamen and the four regions were analyzed separately. CONCLUSION: Our results suggest that STN stimulation does not mediate its anti-PD effects via the release of dopamine, as assessed with [(11)C]raclopride displacement.
Authors: Jonathan M Bledsoe; Christopher J Kimble; Daniel P Covey; Charles D Blaha; Filippo Agnesi; Pedram Mohseni; Sidney Whitlock; David M Johnson; April Horne; Kevin E Bennet; Kendall H Lee; Paul A Garris Journal: J Neurosurg Date: 2009-10 Impact factor: 5.115
Authors: Swen Hesse; Karl Strecker; Dirk Winkler; Julia Luthardt; Christoph Scherfler; Annegret Reupert; Christian Oehlwein; Henryk Barthel; Jens-Peter Schneider; Florian Wegner; Philipp Meyer; Jürgen Meixensberger; Osama Sabri; Johannes Schwarz Journal: J Neurol Date: 2008-05-02 Impact factor: 4.849
Authors: Gwenn S Smith; Kelly A Mills; Greg M Pontone; W Stanley Anderson; Kate M Perepezko; James Brasic; Yun Zhou; Jason Brandt; Christopher R Butson; Daniel P Holt; William B Mathews; Robert F Dannals; Dean F Wong; Zoltan Mari Journal: Parkinsonism Relat Disord Date: 2019-04-16 Impact factor: 4.891
Authors: Nicholas T Vandehey; P Charles Garell; Joseph A Hampel; Dhanabalan Murali; Elizabeth M Smith; Richard Davidson; Alexander K Converse; R Jerry Nickles; Bradley T Christian Journal: J Neurosci Methods Date: 2008-09-09 Impact factor: 2.390
Authors: Hoon-Ki Min; Sun-Chul Hwang; Michael P Marsh; Inyong Kim; Emily Knight; Bryan Striemer; Joel P Felmlee; Kirk M Welker; Charles D Blaha; Su-Youne Chang; Kevin E Bennet; Kendall H Lee Journal: Neuroimage Date: 2012-08-10 Impact factor: 6.556